本帖最后由 老马 于 2012-1-13 21:20 编辑
* m# M6 r W5 p* t1 Y" k" [* @# D; [$ I1 u' @9 @- `
爱必妥和阿瓦斯丁的比较3 q9 y! \& W) j
4 \* G3 o7 D3 I" _
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ Z$ [6 e" l) x. `- H) `" Q1 ~0 g
$ X' k0 b, y( `) q* C5 k8 o: T
! J6 d0 c8 z9 V" Ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
% h$ |8 u9 a7 O$ Z: ^" ]# F1 v, ~==================================================
3 E' W3 ]. G S( {* j2 C& i' AOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)* w$ {- l( [3 I" o/ Z h
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.9 O% j6 k+ }9 j
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 B4 c6 Z& h0 _% T l
|